
Irish software startup nabs $25M Series C to speed up clinical trials
The startup's platform is meant to digitize and modernize the still largely manually and paper-based process of running and managing clinical trials.
The startup's platform is meant to digitize and modernize the still largely manually and paper-based process of running and managing clinical trials.
The company's initial program, known as ND-1000, is a combination of an existing generic cancer medication with a natural product that is meant to boost the effectiveness of CAR T-Cell therapy.
The financing, led by Thiel's Founders Fund, will help the company expand its reach into Europe and Asia while building up its manufacturing capabilities.